Beacon Intelligence to accelerate growth in life sciences R&D intelligence with new investment from Corten Capital
We have advised Corten Capital on its acquisition of Beacon Intelligence (Beacon) from the Hanson Wade Group, itself backed by Graphite Capital.
Beacon was founded in 2015 within the Hanson Wade Group, an events and conferences operator focused on the life sciences industry, to address a critical gap in structured, granular data on early-stage drug development. The Beacon platform is now used daily by over 300 customer organisations globally, including 24 of the world's 30 largest pharmaceutical companies, to track competitive pipelines, identify licensing and acquisition opportunities, and inform R&D investment decisions.
Jonny Bethell, Private Equity Partner said: "We're delighted to have supported Corten on this carveout. Beacon is a unique platform in life sciences development intelligence and we look forward to seeing its progress as standalone business."
Our team was led by Private Equity partner Jonny Bethell and included Emma Danks, Alice Picton, Bradley Mycock, Rob O'Donohoe and Madara Thalduwa (Private Equity); Max Millington and Kelsey Pepper (Banking & Finance); Siân Skelton, Adam Rendle, Adeolu Faniran and Prachi Vasisht (IP); James Ross and Sally Robertson (Tax); Emma Oakley and Francesca Gibbs (Real Estate); Sean Nesbitt and Mark Rose (Employment); and Mark Smith and Afshan Mallik (Pensions).
